查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1414901

急性缺血性脑中风诊断与治疗市场：按类型、最终用户划分：2023-2032 年全球机会分析与产业预测

Acute Ischemic Stroke Diagnosis and Treatment Market By Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 228 Pages | 商品交期: 2-3个工作天内

价格

2022年，急性缺血性脑中风（AIS）诊断及治疗市值为51亿美元，预计2023年至2032年复合年增长率为6.1%，到2032年将达到92亿美元。

由于医疗保健产业对诊断技术的需求不断增加，2023年至2032年，急性缺血性脑中风诊断和治疗市场可能会出现6.1%的显着成长率。

急性缺血性中风诊治市场-IMG1

急性缺血性脑中风（AIS）是成人第四大死因，也是导致残疾的主要原因。这种疾病通常发生在血管阻塞时，导致不可逆的脑损伤和随后的局部神经病变。治疗 AIS 的药理学方法主要是使用Alteplase（也称为重组组织胞浆素原激活剂 (tPA)）进行静脉溶栓。静脉注射Alteplase可透过催化胞浆素原形成蛋白水解酶胞浆素来促进血栓溶解。

由于急性缺血性脑中风诊断和治疗市场正在显着成长。例如，根据世界中风组织2022年全球中风说明书，每年有超过760万例新兴缺血性中风，在全球整体，所有中风中超过62%是缺血性中风。

然而，诊断和治疗缺血性中风的高成本限制了市场成长。例如，根据世界中风组织（WSO）的《柳叶刀公共卫生》论文估计，中风的治疗、康復和间接成本每年超过 7,000 亿美元。因此，高昂的诊断和治疗成本对市场成长有负面影响。

同时，治疗方案持续取得进展，包括溶栓药物，例如：

  • 治疗方案的不断进步，包括Alteplase和血栓切除术等创新机械干预措施，正在推动急性缺血性脑中风市场的成长。这些进展有助于有效且及时地治疗急性缺血性脑中风。

急性缺血性脑中风诊断和治疗市场按类型、最终用户和地区细分。按类型划分，市场分为诊断和治疗。诊断领域进一步分为电脑断层扫描、磁振造影、颈动脉超音波、脑血管摄影、心电图、超音波心臟检查等。治疗环节分为溶栓和机械取栓。溶栓治疗进一步分为组织胞浆素原激活剂、抗血小板剂和其他活性药物。机械取栓段分为血栓摘取支架和抽吸导管，以及组合（血栓摘取支架和抽吸导管）。依最终使用者分类，可分为医院/诊所、诊断实验室/影像中心等。

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 中风发生率增加
      • 成像技术的进步
      • 治疗方案的创新
    • 抑制因素
      • 创新治疗方法高成本
    • 机会
      • 新兴市场的高市场成长潜力

第四章急性缺血性脑中风诊断和治疗市场：按类型

  • 概述
  • 诊断剂
  • 治疗

第五章急性缺血性脑中风诊断与治疗市场：依最终用户分类

  • 概述
  • 医院和诊所
  • 门诊手术中心
  • 诊断实验室和诊断影像中心
  • 其他的

第六章急性缺血性脑中风诊断与治疗市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第七章 竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022年主要企业定位

第八章 公司简介

  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Boehringer Ingelheim International GmbH
  • Koninklijke Philips NV
  • Abbott Laboratories
  • Siemens
  • Medtronic plc
  • Johnson & Johnson
  • Stryker Corporation.
Product Code: A01121

According to a new report published by Allied Market Research, titled, "Acute Ischemic Stroke Diagnosis and Treatment Market," The acute ischemic stroke diagnosis and treatment market was valued at $5.1 billion in 2022, and is estimated to reach $9.2 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. The Acute Ischemic Stroke Diagnosis and Treatment Market is likely to experience a significant growth rate of 6.1% from 2023-2032 owing to increase in demand for diagnostic technology from healthcare sector - Allied Market Research

Acute Ischemic Stroke Diagnosis and Treatment Market - IMG1

Acute ischemic stroke (AIS) stands as the fourth leading cause of death and the primary cause of adult disability. This condition typically arises when a blood vessel obstruction occurs, resulting in irreversible brain injury and subsequent focal neurological deficits. The pharmacological approach to treating AIS revolves around intravenous thrombolysis using an alteplase, also known as recombinant tissue plasminogen activator (tPA). Alteplase administered intravenously facilitates thrombolysis by catalyzing the hydrolysis of plasminogen, forming the proteolytic enzyme plasmin.

The acute ischemic stroke diagnosis and treatment market has experienced significant growth owing to rise in prevalence of ischemic stroke. For instance, according to the World Stroke Organization Global Stroke Fact Sheet 2022, there were over 7.6 million new ischemic strokes each year and globally, over 62% of all incident strokes are ischemic strokes.

However, high cost of ischemic stroke diagnosis and treatment limits the market growth. For instance, according to World Stroke Organization (WSO), the Lancet Public Health article estimated treatment, rehabilitation, and indirect costs for stroke is more than $700 billion annually. Thus, high diagnosis and treatment cost negatively impact the market growth.

On the other hand, ongoing advancements in treatment options, including thrombolytic medications such as alteplase and innovative mechanical interventions like thrombectomy, drive the growth of the acute ischemic stroke market. These developments contribute to effective and timely management of acute ischemic strokes.

The acute ischemic stroke diagnosis and treatment market is segmented into type, end user, and region. By type, the market is segregated into diagnosis, and treatment. The diagnosis segment is further categorized into computed tomography, magnetic resonance imaging, carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others. The treatment segment is bifurcated into thrombolytic therapy and mechanical thrombectomy. The thrombolytic therapy segment is further classified into tissue plasminogen activator, antiplatelet, and others. The mechanical thrombectomy segment is categorized into stent retriever and aspiration catheter, and combination (stent retriever and aspiration catheter). By end user, the market is divided into hospitals & clinics, diagnostic laboratories & diagnostic imaging centers, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

Major key players that operate in the acute ischemic stroke diagnosis and treatment market are AstraZeneca plc, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, GE Healthcare, Koninklijke Philips N.V., Siemens, Abbott Laboratories Medtronic plc, Johnson & Johnson, and Stryker Corporation. Key players have adopted product approval, partnership, and agreement as key developmental strategies to improve the product portfolio of the acute ischemic stroke diagnosis and treatment market.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the acute ischemic stroke diagnosis and treatment market analysis from 2022 to 2032 to identify the prevailing acute ischemic stroke diagnosis and treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the acute ischemic stroke diagnosis and treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global acute ischemic stroke diagnosis and treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Diagnostics
    • Technology
    • Computed Tomography
    • Magnetic Resonance Imaging
    • Carotid Ultrasound
    • Cerebral Angiography
    • Electrocardiography
    • Echocardiography
    • Others
  • Treatment
    • Type
    • Thrombolytic Therapy

Type

    • Mechanical Thrombectomy

Type

By End User

  • Hospitals and Clinics
  • Ambulatory Surgery Centers
  • Diagnostic Laboratories and Imaging Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Boehringer Ingelheim International GmbH
    • AstraZeneca plc
    • Abbott Laboratories
    • Stryker Corporation.
    • Siemens
    • Medtronic plc
    • Johnson & Johnson
    • F. Hoffmann-La Roche Ltd.
    • Koninklijke Philips N.V.
    • GE Healthcare

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in incidence of stroke
      • 3.4.1.2. Advancements in imaging technologies
      • 3.4.1.3. Innovations in treatment option
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of innovative therapies
    • 3.4.3. Opportunities
      • 3.4.3.1. High market growth potential in emerging markets

CHAPTER 4: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Diagnostics
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Diagnostics Acute Ischemic Stroke Diagnosis and Treatment Market by Technology
  • 4.3. Treatment
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
    • 4.3.4. Treatment Acute Ischemic Stroke Diagnosis and Treatment Market by Type
      • 4.3.4.1. Thrombolytic Therapy Acute Ischemic Stroke Diagnosis and Treatment Market by Type
      • 4.3.4.2. Mechanical Thrombectomy Acute Ischemic Stroke Diagnosis and Treatment Market by Type

CHAPTER 5: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospitals and Clinics
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Ambulatory Surgery Centers
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Diagnostic Laboratories and Imaging Centers
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Type
    • 6.2.3. Market size and forecast, by End User
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Type
      • 6.2.4.1.2. Market size and forecast, by End User
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Type
      • 6.2.4.2.2. Market size and forecast, by End User
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Type
      • 6.2.4.3.2. Market size and forecast, by End User
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Type
    • 6.3.3. Market size and forecast, by End User
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Type
      • 6.3.4.1.2. Market size and forecast, by End User
      • 6.3.4.2. France
      • 6.3.4.2.1. Market size and forecast, by Type
      • 6.3.4.2.2. Market size and forecast, by End User
      • 6.3.4.3. UK
      • 6.3.4.3.1. Market size and forecast, by Type
      • 6.3.4.3.2. Market size and forecast, by End User
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Market size and forecast, by Type
      • 6.3.4.4.2. Market size and forecast, by End User
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Market size and forecast, by Type
      • 6.3.4.5.2. Market size and forecast, by End User
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Market size and forecast, by Type
      • 6.3.4.6.2. Market size and forecast, by End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Type
    • 6.4.3. Market size and forecast, by End User
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Market size and forecast, by Type
      • 6.4.4.1.2. Market size and forecast, by End User
      • 6.4.4.2. China
      • 6.4.4.2.1. Market size and forecast, by Type
      • 6.4.4.2.2. Market size and forecast, by End User
      • 6.4.4.3. India
      • 6.4.4.3.1. Market size and forecast, by Type
      • 6.4.4.3.2. Market size and forecast, by End User
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Market size and forecast, by Type
      • 6.4.4.4.2. Market size and forecast, by End User
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Market size and forecast, by Type
      • 6.4.4.5.2. Market size and forecast, by End User
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Type
      • 6.4.4.6.2. Market size and forecast, by End User
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Type
    • 6.5.3. Market size and forecast, by End User
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Type
      • 6.5.4.1.2. Market size and forecast, by End User
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Market size and forecast, by Type
      • 6.5.4.2.2. Market size and forecast, by End User
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Market size and forecast, by Type
      • 6.5.4.3.2. Market size and forecast, by End User
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Market size and forecast, by Type
      • 6.5.4.4.2. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. AstraZeneca plc
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. F. Hoffmann-La Roche Ltd.
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
  • 8.3. GE Healthcare
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Boehringer Ingelheim International GmbH
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Koninklijke Philips N.V.
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Abbott Laboratories
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
  • 8.7. Siemens
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Medtronic plc
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Johnson & Johnson
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Stryker Corporation.
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL DIAGNOSTICS ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 04. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL TREATMENT ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL THROMBOLYTIC THERAPY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL MECHANICAL THROMBECTOMY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 09. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTIC LABORATORIES AND IMAGING CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. U.S. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 20. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 29. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. UK ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. UK ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. REST OF EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. REST OF ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. REST OF ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 56. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. SAUDI ARABIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. SAUDI ARABIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. SOUTH AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. REST OF LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 65. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 66. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 67. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 68. ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 69. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 70. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 71. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 72. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 73. GE HEALTHCARE: KEY EXECUTIVES
  • TABLE 74. GE HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 75. GE HEALTHCARE: PRODUCT SEGMENTS
  • TABLE 76. GE HEALTHCARE: SERVICE SEGMENTS
  • TABLE 77. GE HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 78. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 79. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 80. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
  • TABLE 81. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 82. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 83. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 84. KONINKLIJKE PHILIPS N.V.: PRODUCT SEGMENTS
  • TABLE 85. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 86. KONINKLIJKE PHILIPS N.V.: KEY STRATERGIES
  • TABLE 87. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 88. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 89. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 90. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 91. SIEMENS: KEY EXECUTIVES
  • TABLE 92. SIEMENS: COMPANY SNAPSHOT
  • TABLE 93. SIEMENS: PRODUCT SEGMENTS
  • TABLE 94. SIEMENS: PRODUCT PORTFOLIO
  • TABLE 95. SIEMENS: KEY STRATERGIES
  • TABLE 96. MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 97. MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 98. MEDTRONIC PLC: PRODUCT SEGMENTS
  • TABLE 99. MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 100. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 101. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 102. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 103. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 104. STRYKER CORPORATION.: KEY EXECUTIVES
  • TABLE 105. STRYKER CORPORATION.: COMPANY SNAPSHOT
  • TABLE 106. STRYKER CORPORATION.: PRODUCT SEGMENTS
  • TABLE 107. STRYKER CORPORATION.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET (2023-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR TREATMENT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTIC LABORATORIES AND IMAGING CENTERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 20. U.S. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. UK ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. REST OF EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SAUDI ARABIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43. COMPETITIVE DASHBOARD
  • FIGURE 44. COMPETITIVE HEATMAP: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET
  • FIGURE 45. TOP PLAYER POSITIONING, 2022
  • FIGURE 46. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 50. GE HEALTHCARE: NET REVENUE, 2021-2022 ($MILLION)
  • FIGURE 51. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. GE HEALTHCARE: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. KONINKLIJKE PHILIPS N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. KONINKLIJKE PHILIPS N.V.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 58. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. SIEMENS: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. SIEMENS: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 65. SIEMENS: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. SIEMENS: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. MEDTRONIC PLC: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 68. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 69. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 70. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 72. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 73. STRYKER CORPORATION.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 74. STRYKER CORPORATION.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 75. STRYKER CORPORATION.: REVENUE SHARE BY REGION, 2022 (%)